Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00245362 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by Cell Genesys.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00245362: Completed Phase 2 study, sponsored by Cell Genesys.
NCT00245362 is a Phase 2 study that has completed, run by Cell Genesys. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00245362, a Phase 2 study, has completed, sponsored by Cell Genesys.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
To evaluate the safety and effectiveness of CG8020 and CG2505.
Interventions
- BIOLOGICAL CG 8020 and CG 2505
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2002-06 |
| Est. Completion | 2004-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00245362
The ClinicalTrials.gov registry entry for NCT00245362 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cell Genesys, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CG 8020 and CG 2505 is the first listed.
NCT00245362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00245362 about?
NCT00245362 is a clinical study titled "A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer". To evaluate the safety and effectiveness of CG8020 and CG2505.
What is the current status of trial NCT00245362?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2002-06. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00245362?
The interventions under investigation include: CG 8020 and CG 2505 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00245362?
This trial is sponsored by Cell Genesys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.